216 related articles for article (PubMed ID: 24571259)
1. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of HGAL and LMO2 in follicular lymphoma].
Zhang F; Luo D; Luo X; Chen Y; Xu J; Chen J; Zhuang H; Liu Y
Zhonghua Bing Li Xue Za Zhi; 2016 Feb; 45(2):83-5. PubMed ID: 26879427
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
4. Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.
Berker N; Yeğen G; Özlük Y; Doğan Ö
Turk J Haematol; 2023 Aug; 40(3):162-173. PubMed ID: 37519110
[TBL] [Abstract][Full Text] [Related]
5. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components.
Younes SF; Beck AH; Lossos IS; Levy R; Warnke RA; Natkunam Y
Am J Surg Pathol; 2010 Sep; 34(9):1266-76. PubMed ID: 20697248
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.
Verdanet E; Dereure O; René C; Tempier A; Benammar-Hafidi A; Gallo M; Frouin E; Durand L; Gazagne I; Costes-Martineau V; Cacheux V; Szablewski V
Histopathology; 2017 Oct; 71(4):648-660. PubMed ID: 28594133
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
8. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Min M; Lin L; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):110-6. PubMed ID: 22780928
[TBL] [Abstract][Full Text] [Related]
10. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.
Chen BB; Xu XP; Shen L; Han TJ; Lin ZG; Chen Z; Kang H; Huang B; Lin GW
Chin Med J (Engl); 2013 Feb; 126(3):482-7. PubMed ID: 23422111
[TBL] [Abstract][Full Text] [Related]
12. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
Cady FM; O'Neill BP; Law ME; Decker PA; Kurtz DM; Giannini C; Porter AB; Kurtin PJ; Johnston PB; Dogan A; Remstein ED
J Clin Oncol; 2008 Oct; 26(29):4814-9. PubMed ID: 18645192
[TBL] [Abstract][Full Text] [Related]
13. PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.
Cubedo E; Maurin M; Jiang X; Lossos IS; Wright KL
FEBS J; 2011 Sep; 278(17):3065-75. PubMed ID: 21722313
[TBL] [Abstract][Full Text] [Related]
14. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
18. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
Moore EM; Swerdlow SH; Gibson SE
Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]